About the Centre*
A scientific revolution is in the making. In a few years time, all known genetic risk factors for diseases could be routinely determined at birth. Using large-scale molecular interrogation methods, powered by advances in mathematics and computer science, a patient’s particular disease subtypes could be identified and the best available treatment selected. Outcomes of patient tailored treatments will be valuable for the development of new diagnostic approaches and drug designs that specifically target aberrant molecular pathways present in diseased cells with minimal interference on healthy ones. This is the promise of personalised information-based medicine.
The core aim of the research conducted by this Centre is the delivery of "bench-to-bedside” research by combining the often disparate disciplines of bioinformatics, molecular and genetic analysis, clinical information and population data. The Centre for Bioinformatics, Biomarker Discovery & Information-Based Medicine (CIBM)* aims to find methodologies that will shorten the process of obtaining novel discoveries and to use them to obtain distinctively better outcomes in clinical practice and translational individualised medicine.
*Formerly, The Newcastle Bioinformatics Initiative (NBI).
Contact Us
The Centre for Bioinformatics, Biomarker Discovery & Information-Based Medicine
The University of Newcastle
Callaghan NSW 2308
Australia
Centre Manager
Lee-Anne Marsh
Phone: +61 (2) 4921 6953
Fax: +61 (2) 4921 6929
Email
Centre Directors
Prof. Rodney Scott
School of Biomedical Sciences
Phone: +61 (2) 4921 4974
Fax: +61 (2) 4921 4253
Email
A/Prof. Pablo Moscato
School of Electrical Engineering and Computer Science
Phone: +61 (2) 4921 6056
Fax: +61 (2) 4921 6929
Email
News in Brief
June 2009
MS affects 2.5 million people worldwide including almost 20,000 Australians. The causes of MS are unknown but are thought to be a combination of genetic predisposition and environmental factors. A recent article in Nature Genetics finds two new genes implicated in the development of Multiple Sclerosis (MS) that were not previously linked to the disease. The discovery was made by the ANZgene consortium - a collaboration of Australian and New Zealand researchers that includes CIBM members. (more)
Congratulations to Osvaldo Rosso on his recent appointment as associate editor of BMC Neuroscience.
